Compare NBY & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBY | SOPH |
|---|---|---|
| Founded | 2000 | 2011 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 330.4M |
| IPO Year | 2007 | 2021 |
| Metric | NBY | SOPH |
|---|---|---|
| Price | $15.78 | $5.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 3.2M | 89.9K |
| Earning Date | 11-07-2025 | 03-03-2026 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | $10,302,000.00 | ★ $73,297,000.00 |
| Revenue This Year | $23.91 | $18.32 |
| Revenue Next Year | $32.05 | $15.61 |
| P/E Ratio | $493.09 | ★ N/A |
| Revenue Growth | ★ 390.34 | 13.66 |
| 52 Week Low | $0.46 | $2.58 |
| 52 Week High | $19.95 | $5.55 |
| Indicator | NBY | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 69.49 | 62.35 |
| Support Level | $10.42 | $5.04 |
| Resistance Level | $19.95 | $5.55 |
| Average True Range (ATR) | 3.14 | 0.31 |
| MACD | 0.59 | 0.04 |
| Stochastic Oscillator | 73.24 | 71.55 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.